Yuekang Pharmaceuticals (688658.SH): Indications for YKYY017 aerosol inhalation for the prevention and treatment of respiratory infections related to coronavirus have received FDA clinical trial approval.

Sina Finance App News, Yutian Pharmaceutical Co., Ltd. (688658.SH) announced that the company recently received a letter from the US Food and Drug Administration (FDA) approving the clinical trial application for YKYY017 nebulized inhalation solution for the prevention and treatment of respiratory tract infections related to the coronavirus.